FDA approve Fast Track Designation for encaleret for the treatment of Autosomal Dominant Hypocalcaemia Type 1 (ADH1)

Encaleret is an investigational small molecule antagonist of the calcium sensing receptor. Data to support fast track designation comes from a phase 2b proof of concept study which found it normalised calcium in 100% of ADH1 participants over 5 days.

Source:

Biospace Inc.